MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol. 2020 04 01; 38(10):1059-1069.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Doxorubicin
Female
Heterocyclic Compounds, 3-Ring
Humans
Middle Aged
Neoadjuvant Therapy
Paclitaxel
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Receptor, ErbB-2
Receptors, Steroid
Trastuzumab

authors with profiles

Nora T. Jaskowiak
Rita Nanda
Jeffrey B. Matthews